# reload+after+2024-01-20 10:44:45.946125
address1§500 Technology Square
address2§Suite 700
city§Cambridge
state§MA
zip§02139
country§United States
phone§617 586 3100
website§https://foghorntx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia and myelodysplastic syndrome; and FHD-609, a small molecule protein degrader for BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Loxo Oncology to create novel oncology medicines. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§161
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Adrian H. B. Gottschalk', 'age': 47, 'title': 'President, CEO & Director', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 790625, 'exercisedValue': 0, 'unexercisedValue': 3071702}, {'maxAge': 1, 'name': 'Dr. Allan  Reine M.D.', 'age': 48, 'title': 'Chief Financial Officer', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 565500, 'exercisedValue': 0, 'unexercisedValue': 529726}, {'maxAge': 1, 'name': 'Dr. Steven F. Bellon Ph.D.', 'age': 58, 'title': 'Chief Scientific Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 565500, 'exercisedValue': 0, 'unexercisedValue': 4942}, {'maxAge': 1, 'name': 'Mr. Michael J. LaCascia', 'age': 58, 'title': 'Chief Legal Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 565500, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gerald R. Crabtree M.d.', 'title': 'Founder & Member of Scientific Advisory Board', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Saurabh  Sewak Ph.D.', 'title': 'Vice President of Corporate Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Carlos  Costa', 'age': 50, 'title': 'Chief People Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Fanny  Cavalie', 'age': 45, 'title': 'Chief Strategy & Business Operations Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alfonso Quintas Cardama M.D.', 'age': 52, 'title': 'Chief Medical Officer', 'yearBorn': 1971, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§4
boardRisk§6
compensationRisk§7
shareHolderRightsRisk§5
overallRisk§6
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.68
priceToSalesTrailing12Months§7.3105445
currency§USD
dateShortInterest§1702598400
forwardEps§-2.25
exchange§NGM
quoteType§EQUITY
shortName§Foghorn Therapeutics Inc.
longName§Foghorn Therapeutics Inc.
firstTradeDateEpochUtc§1603459800
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§abad74ee-88c2-3fa2-8f10-1f935407d35f
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§6.0
targetMeanPrice§13.75
targetMedianPrice§14.5
recommendationMean§2.0
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§4.997
grossMargins§-2.4907
ebitdaMargins§0.0
trailingPegRatio§None
